Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 46,250 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00.
• On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $36.74, for a total value of $679,690.00.
• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $42.45 on Friday. The firm has a market capitalization of $3.05 billion, a P/E ratio of -7.66 and a beta of 0.92. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The firm’s fifty day moving average price is $36.50 and its two-hundred day moving average price is $41.10. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the company posted ($0.81) earnings per share. As a group, research analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Vera Therapeutics News Roundup

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA’s accelerated approval of Trutakna is a major commercial milestone for Vera Therapeutics and the clearest driver behind the stock’s recent strength. FDA grants accelerated approval to Vera Therapeutics’ Trutakna
• Positive Sentiment: HC Wainwright raised its price target to $125 and kept a buy rating, signaling confidence in Vera’s launch opportunity and longer-term upside. Vera Therapeutics had its price target raised by HC Wainwright from $110.00 to $125.00.
• Positive Sentiment: Wedbush increased its price target to $43, reflecting continued analyst support even after the FDA news-driven rally. Vera Therapeutics had its price target raised by Wedbush from $35.00 to $43.00.
• Neutral Sentiment: The company announced a planned transition in its chief regulatory officer role, with Nancy Boman appointed and William Turner set to retire; this looks like routine leadership succession rather than a major strategic shift. Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
• Negative Sentiment: CEO Marshall Fordyce sold 46,250 shares under a pre-arranged 10b5-1 plan, a move that may weigh slightly on sentiment even though it was scheduled in advance. SEC filing for CEO Marshall Fordyce stock sale

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on VERA shares. Wedbush lifted their price objective on shares of Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a research report on Wednesday. The Goldman Sachs Group reissued a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. TD Cowen raised their target price on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday. Bank of America lifted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Guggenheim upped their price target on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $84.58.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after purchasing an additional 1,795,537 shares during the period. Vestal Point Capital LP increased its holdings in shares of Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after purchasing an additional 600,000 shares during the period. Integral Health Asset Management LLC raised its position in shares of Vera Therapeutics by 47.8% in the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after buying an additional 550,000 shares in the last quarter. Elmind Capital LP acquired a new stake in shares of Vera Therapeutics in the fourth quarter valued at approximately $24,434,000. Finally, Braidwell LP acquired a new stake in shares of Vera Therapeutics in the third quarter valued at approximately $13,738,000. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.